Get the Stockscreener App
25.16
1.37%
0.34
After Hours:
25.16
Apellis Pharmaceuticals Inc stock is traded at $25.16, with a volume of 864.30K.
It is up +1.37% in the last 24 hours and up +24.99% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$24.82
Open:
$24.88
24h Volume:
864.30K
Relative Volume:
0.33
Market Cap:
$3.18B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-12.39
EPS:
-2.03
Net Cash Flow:
$-205.58M
1W Performance:
-0.16%
1M Performance:
+24.99%
6M Performance:
+35.20%
1Y Performance:
-24.49%
1-Day Range:
$24.74
$25.20
1-Week Range:
$24.25
$26.12
52-Week Range:
$16.10
$35.57
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
25.16 | 3.14B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - Bollywood Helpline
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX) - The Globe and Mail
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating - 富途牛牛
Will Apellis Pharmaceuticals Inc. (1JK) stock outperform foreign stocksEarnings Risk Report & Reliable Volume Spike Trade Alerts - Улправда
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peers2025 Retail Activity & Free Technical Pattern Based Buy Signals - Улправда
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekersWeekly Trade Recap & High Conviction Buy Zone Picks - Улправда
Will Apellis Pharmaceuticals Inc. stock see PE expansion2025 Trading Recap & Reliable Price Breakout Signals - Улправда
Stifel maintains Apellis Pharmaceuticals (APLS) buy recommendation - MSN
APLS (Apellis Pharmaceuticals) EV-to-OCF : 39.23 (As of Dec. 19, 2025) - GuruFocus
Apellis Pharmaceuticals stock price target lowered to $48 at Stifel By Investing.com - Investing.com Canada
Stifel Lowers Price Target for Apellis Pharmaceuticals (APLS) to $48 | APLS Stock News - GuruFocus
Stifel Nicolaus Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00 - MarketBeat
Is Apellis Pharmaceuticals Inc. stock near bottom after decline2025 Pullback Review & AI Forecasted Entry and Exit Points - DonanımHaber
What technical charts say about Apellis Pharmaceuticals Inc. stock2025 Technical Overview & Comprehensive Market Scan Insights - Улправда
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 5,000 Shares of Stock - MarketBeat
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
Officer Watson Sells 5,000 ($122.5K) Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Investors in Apellis Pharmaceuticals (NASDAQ:APLS) From Five Years Ago Are Still Down 54%, Even After 3.2% Gain This Past Week - 富途牛牛
Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
Hudson Bay Capital Management LP Has $8.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis stock rating reiterated at Outperform by William Blair - Investing.com Canada
Squarepoint Ops LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Braidwell LP Sells 531,300 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
683 Capital Management LLC Buys 77,000 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha
Natixis Sells 564,361 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Camber Capital Management LP Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Low Cost Wealth Building - earlytimes.in
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Apellis Pharmaceuticals, Inc. $APLS Shares Purchased by Amundi - MarketBeat
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Would You Still Hold Apellis Pharmaceuticals Stock If It Fell 30%? - Trefis
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis Pharmaceuticals (APLS): Valuation Check After Positive EMPAVELI Kidney Data and New FDA Approval - Yahoo Finance
Schroder Investment Management Group Grows Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
What downside risks could hit Apellis Pharmaceuticals Inc. (1JK) stockRecession Risk & AI Optimized Trade Strategies - Newser
Why millennials buy Apellis Pharmaceuticals Inc. (1JK) stockPrice Action & High Accuracy Trade Alerts - Newser
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Will Apellis Pharmaceuticals Inc. (1JK) stock issue positive guidanceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Why Apellis Pharmaceuticals Inc. (1JK) stock gets analyst attentionRate Cut & High Conviction Buy Zone Picks - Newser
Apellis’ EMPAVELI shows 68% reduction in proteinuria for rare kidney diseases - Investing.com Nigeria
Apellis Reports Positive Phase 3 Results for Its Kidney Disease Treatment Empaveli - marketscreener.com
Apellis (APLS) Gains Boost from Positive Phase 3 Study Results - GuruFocus
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):